Optimizing and Profiling Prostaglandin E2 as a Medical Countermeasure for the Hematopoietic Acute Radiation Syndrome

• Published in: Radiation research Vol. 195; no. 2; p. 115
• Main Authors: Patterson, Andrea M, Wu, Tong, Chua, Hui Lin, Sampson, Carol H, Fisher, Alexa, Singh, Pratibha, Guise, Theresa A, Feng, Hailin, Muldoon, Jessica, Wright, Laura, Plett, P Artur, Pelus, Louis M, Orschell, Christie M
• Format: Journal Article
• Language: English
• Published: United States 01.02.2021
• Subjects: Acute Radiation Syndrome - drug therapy; Acute Radiation Syndrome - genetics; Acute Radiation Syndrome - pathology; Animals; Dinoprostone - analogs & derivatives; Dinoprostone - genetics; Dinoprostone - pharmacology; Dose-Response Relationship, Radiation; Gamma Rays - adverse effects; Gene Expression Regulation - drug effects; Gene Expression Regulation - radiation effects; Granulocyte Colony-Stimulating Factor - genetics; Hematopoiesis - drug effects; Hematopoiesis - radiation effects; Hematopoietic Stem Cells - drug effects; Hematopoietic Stem Cells - radiation effects; Humans; Interleukin-6 - genetics; Mice; Radiation Tolerance - drug effects; Radiation Tolerance - genetics; Radiation-Protective Agents - pharmacology; Sequence Analysis, RNA; Whole-Body Irradiation

Identification of medical countermeasures (MCM) to mitigate radiation damage and/or protect first responders is a compelling unmet medical need. The prostaglandin E2 (PGE2) analog, 16,16 dimethyl-PGE2 (dmPGE2), has shown efficacy as a radioprotectant and radiomitigator that can enhance hematopoiesis...